Please ensure Javascript is enabled for purposes of website accessibility

CDC: Gilead Sciences' Remdesivir Is Being Used to Treat Coronavirus Patients

By Prosper Junior Bakiny - Mar 11, 2020 at 9:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Remdesivir is still in phase 3 testing, but desperate times call for desperate measures.

The latest headlines regarding the COVID-19 outbreak aren't good. As of March 11, there are more than 1,200 confirmed cases of the disease in the U.S., and more than 30 people have died from it. Worldwide, there are more than 110,000 confirmed cases and more than 4,200 deaths.  The World Health Organization (WHO) has officially declared COVID-19 a pandemic, and things could get worse before they get better. Several drugmakers are currently trying to find a vaccine or a treatment for the rapidly spreading disease, and arguably the leader in this race is Gilead Sciences (GILD -0.03%)

Gilead Sciences' remdesivir -- a drug that was originally developed to treat Ebola but with little success -- is currently being investigated as a treatment for COVID-19. However, according to the director of the U.S. Centers for Disease Control and Prevention (CDC), Robert Redfield, remdesivir is already being given to COVID-19 patients. The U.S. Food and Drug Administration allows patients in the U.S. to use unapproved drugs in "life-threatening" situations when there are no other options, which explains why COVID-19 patients are permitted to take remdesivir. 

A woman in scrubs holding a test tube with blood for Coronavirus testing.

Image source: Getty Images.

Gilead Sciences is racing through the process

On Feb. 26, Gilead Sciences announced the initiation of two phase 3 studies to investigate the efficacy of remdesivir as a treatment for COVID-19.  The pharma giant will give oral doses of remdesivir for five or 10 days to patients with both mild and severe manifestations of the disease. If the results from these studies are positive, Gilead Sciences should move on to the next step in the regulatory process and submit remdesivir for approval to health authorities. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.34 (-0.03%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.